Status:
UNKNOWN
Furosemide Alone or Unexpectedly With Solution of Hypertonic Saline in Nephrotic Syndrome
Lead Sponsor:
Medical University of Bialystok
Conditions:
Nephrotic Syndrome
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The trial will test the hypothesis that hypertonic saline on top of standard diuretic treatment will help achieve adequate diuresis in patients with nephrotic syndrome.
Detailed Description
Objectives: Edema is one of the major clinical manifestations of nephrotic syndrome. All patients are initially treated with diuretics and sodium restriction but the results are sometimes not satisfa...
Eligibility Criteria
Inclusion
- 30 consecutive patients with nephrotic syndrome (proteinuria over 3.5 g/day, edema, hypoalbuminemia, dysproteinemia) admitted to II Nephrology Department from November 2018 onwards within 48h of admission,
- age above 18,
- informed consent.
Exclusion
- AKI (acute kidney injury) - AKIN criteria level 3,
- CKD (chronic kidney disease) stage 4 and 5 according to KDIGO (Kidney Disease: Improving Global Outcomes),
- concomittant heart failure NYHA (New York Heart Association) class III or worse,
- active liver disease and liver failure,
- terminal neoplastic disease,
- serum sodium above 145 mmol/l,
- pregnancy.
Key Trial Info
Start Date :
December 15 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2023
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03750136
Start Date
December 15 2018
End Date
March 1 2023
Last Update
November 23 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
II Department of Nephrology and Hypertension
Bialystok, Poland, 15-276